Pravin U. Dugel, MD

These novel strategies may change DME treatment paradigmThere is subset of patients with resistant or persistent DME that forms the impetus for new treatment strategies, including next-generation anti-VEGF-A and new classes of drugs. Pravin U. Dugel, MD, outlines a list of potential treatment candidates that may lead that paradigm shift.
Novel brolucizumab fosters as real-world alternative for nAMDTopline results from phase III studies investigating intravitreal brolucizumab (Novartis) for treatment of neovascular age-related macular degeneration (nAMD) support the potential of this novel anti-VEGF antibody to meet the real-world need for an alternative agent with a sustainable therapeutic regimen.
27-gauge presents new paradigm of intraocular precision for vitrectomyModern 27-gauge equipment for vitrectomy has introduced a new paradigm in vitreoretinal surgery marked by enhanced precision and control.
Anti-PDGF inhibitor development continues despite negative resultsDespite the failure of 2 clinical trials involving a combination therapy of platelet-derived growth factor (PDGF) inhibitor and anti-vascular endothelial growth factor (anti-VEGF) therapy, a third phase III study continues.
Findings reaffirm ocriplasmin success for symptomatic VMA over long termResults of a 2-year phase IIIb study include findings consistent with earlier information about treatment success with ocriplasmin injection for symptomatic vitreomacular adhesion and new information about efficacy and safety over the longer term.
Introducing 3-D OCT to live surgery
Introducing 3-D OCT to live surgeryThe advent of three-dimensional optical coherence tomography to live surgery may bring greater clarity to how ophthalmologists visualize structures and how they operate.
Consider PDGF treatment prior to anti-VEGF therapyPatients with age-related macular degeneration patients who had received anti-platelet derived growth factor (PDGF) therapy prior to anti-VEGF treatment fared better than those who did not in a pilot study.
Drugs for AMD and DME still in center courtMuch of the developments in pharmacologic therapy for retina disease revolved around age-related macular degeneration and diabetic macular edema in 2014.
Instrumentation, imaging advances make retina surgery saferFor retinal surgery, the latest generation of instrumentation is anticipated to be accompanied by markedly improved fluidics, precision, and faster patient recovery.
Laser advances take retina specialty to new levels of treatment, careDevelopments in lasers, along with genetic engineering, are showing promise as technologies that may shape the future of retina treatment.